HRP20191807T4 - Bjelančevinasti heterodimer i njegova uporaba - Google Patents

Bjelančevinasti heterodimer i njegova uporaba Download PDF

Info

Publication number
HRP20191807T4
HRP20191807T4 HRP20191807TT HRP20191807T HRP20191807T4 HR P20191807 T4 HRP20191807 T4 HR P20191807T4 HR P20191807T T HRP20191807T T HR P20191807TT HR P20191807 T HRP20191807 T HR P20191807T HR P20191807 T4 HRP20191807 T4 HR P20191807T4
Authority
HR
Croatia
Prior art keywords
antibody
complex
terminus
region
protein
Prior art date
Application number
HRP20191807TT
Other languages
English (en)
Inventor
Ting Xu
Yan LUAN
Jianjian PENG
Shuli MA
Meng Zhao
Xiaoxiao Wang
Hui Ma
Shilong FU
Xiaolong PAN
Shanshan NING
Original Assignee
Dingfu Biotarget Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52640678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191807(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dingfu Biotarget Co., Ltd filed Critical Dingfu Biotarget Co., Ltd
Publication of HRP20191807T1 publication Critical patent/HRP20191807T1/hr
Publication of HRP20191807T4 publication Critical patent/HRP20191807T4/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

1. Bjelančevinasti kompleks, koji sadrži (1) teški lanac i laki lanac antitijela specifičnih za tumorski antigen; i (2) fuzijski protein koji se sastoji od, od N-kraja do C-kraja, jedan ili više imunoregulatora spojenih na područje antitijela Fc, opcionalno pomoću jednog ili više veznika, pri čemu područje antitijela Fc kompleksa s teškim lancem (1) tvori heterodimer, pri čemu je imunoregulator interleukin 10 i tumorski antigen je EGFR.
2. Bjelančevinasti kompleks u skladu s bilo kojim od patentnih zahtjeva 1, pri čemu se fuzijski protein sastoji od, od N-kraja do C-kraja, dva ili više imunoregulatora međusobno spojenih unutar okvira i spojenih na područje antitijela Fc, opcionalno s jednim ili više veznika.
3. Bjelančevinasti kompleks u skladu s bilo kojim od patentnih zahtjeva 1-2, pri čemu navedeni teški lanac antitijela specifičnog za tumorski antigen i navedeno područje antitijela Fc fuzijskog proteina, svaki sadrži heterodimerizacijsku sekvencu.
4. Izolirani polinukleotid koji kodira bjelančevinasti kompleks u skladu s bilo kojim od patentnih zahtjeva 1-3.
5. Izolirana stanica domaćina koja sadrži izolirani polinukleotid u skladu s patentnim zahtjevom 4.
6. Bjelančevinasti kompleks u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, za uporabu u sprječavanju rasta tumora ili tumorske stanice.
7. Način proizvodnje bjelančevinastog kompleksa, sadržava (i) kultiviranje stanice domaćina u skladu s patentnim zahtjevom 5 u uvjetima u kojima se postiže izraz navedenog kompleksa i (ii) skupljanje navedenog izraženog kompleksa.
HRP20191807TT 2014-11-24 2015-11-10 Bjelančevinasti heterodimer i njegova uporaba HRP20191807T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410681422.XA CN104403004B (zh) 2014-11-24 2014-11-24 抗体‑干扰素异二聚体的制备和用途
EP15862694.5A EP3227342B2 (en) 2014-11-24 2015-11-10 Proteinaceous heterodimer and use thereof
PCT/CN2015/094235 WO2016082677A1 (en) 2014-11-24 2015-11-10 Proteinaceous heterodimer and use thereof

Publications (2)

Publication Number Publication Date
HRP20191807T1 HRP20191807T1 (hr) 2019-12-27
HRP20191807T4 true HRP20191807T4 (hr) 2023-09-29

Family

ID=52640678

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191807TT HRP20191807T4 (hr) 2014-11-24 2015-11-10 Bjelančevinasti heterodimer i njegova uporaba

Country Status (9)

Country Link
US (2) US10471124B2 (hr)
EP (1) EP3227342B2 (hr)
JP (1) JP6851314B6 (hr)
CN (2) CN104403004B (hr)
DK (1) DK3227342T4 (hr)
ES (1) ES2752248T5 (hr)
FI (1) FI3227342T4 (hr)
HR (1) HRP20191807T4 (hr)
WO (1) WO2016082677A1 (hr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
ES2824151T3 (es) 2014-12-19 2021-05-11 Alkermes Inc Proteínas de fusión Fc monocatenarias
UY37030A (es) * 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
WO2017134305A1 (en) * 2016-02-05 2017-08-10 Orionis Biosciences Nv Bispecific signaling agents and uses thereof
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
PT3565828T (pt) 2017-01-05 2022-02-08 Kahr Medical Ltd Proteína de fusão sirp1 alfa-41bbl e seus métodos de utilização
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
CN108948195B (zh) * 2017-05-23 2022-05-31 胡毅 一种抗egfr/pd-l1双靶向抗体、其制备方法及用途
EP3638700A4 (en) * 2017-06-14 2021-04-21 Dingfu Biotarget Co., Ltd PROTEINOUS HETERODIMER AND USE OF IT
PT3661954T (pt) 2017-08-03 2022-04-14 Amgen Inc Muteínas de interleuquina-21 e métodos de tratamento
US11987609B2 (en) 2017-09-25 2024-05-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
CN111132998B (zh) 2017-09-25 2024-01-30 苏州丁孚靶点生物技术有限公司 用于癌症治疗的方法和组合物
EP3688022A4 (en) * 2017-09-29 2021-09-22 NantCell, Inc. ANTIGEN PROTEINS AND PROCEDURES FOR THEREFORE
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
WO2019140196A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Anti-pd-1 antibodies and methods of treatment
CN113166220A (zh) * 2018-03-09 2021-07-23 奥美药业有限公司 创新细胞因子前药
CN108727504B (zh) * 2018-04-16 2021-08-27 泉州向日葵生物科技有限公司 一种ifn与抗pd-l1抗体的融合蛋白及其应用
US20210253639A1 (en) * 2018-05-16 2021-08-19 Regents Of The University Of Michigan Heterodimeric peptide reagents and methods
CN108715833B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种负载血小板裂解液的微球制备方法
JP7439372B2 (ja) * 2018-06-21 2024-02-28 シャタック ラボ，インコーポレイテッド ヘテロ二量体タンパク質及びその使用
CA3120474A1 (en) 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
KR20210139312A (ko) * 2019-03-06 2021-11-22 데카 바이오사이언시즈, 인크. Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
WO2020192648A1 (en) * 2019-03-25 2020-10-01 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
US11512122B2 (en) 2019-05-17 2022-11-29 Xencor, Inc. IL-7-FC-fusion proteins
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
US20220235133A1 (en) * 2019-06-24 2022-07-28 Nanjing GenScript Biotech Co., Ltd. Monoclonal antibody-cytokine fusion protein dimer and application thereof
WO2021005599A1 (en) * 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
CN110256583B (zh) * 2019-07-11 2022-05-20 中国科学院生物物理研究所 一种il-2突变体与抗体的融合蛋白及其应用
US20220112258A1 (en) * 2019-07-25 2022-04-14 I-Mab Biopharma Us Limited Bifunctional molecules with il-7 activity
CN113429476A (zh) * 2020-03-23 2021-09-24 泰州迈博太科药业有限公司 一种结合冠状病毒的双功能融合蛋白、其制备方法及应用
TW202204387A (zh) * 2020-03-31 2022-02-01 南韓商韓美藥品股份有限公司 新穎免疫刺激ｉｌ－２類似物
CA3183151A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
WO2022000136A1 (en) * 2020-06-28 2022-01-06 Dingfu Biotarget Co., Ltd. Methods and compositions for cancer treatment
AU2021301953A1 (en) * 2020-07-01 2023-02-09 Institute Of Biophysics, Chinese Academy Of Sciences Construction and application of fusion protein vaccine platform
KR20230096959A (ko) 2020-07-20 2023-06-30 데카 바이오사이언시즈, 인크. Il-10을 포함하는 이중 시토카인 융합 단백질
CN114316064A (zh) * 2020-10-10 2022-04-12 广东菲鹏制药股份有限公司 融合蛋白及其应用
WO2023060165A2 (en) * 2021-10-06 2023-04-13 Elixiron Immunotherapeutics (hong Kong) Limited Interleukin-10 muteins and fusion proteins thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
DK1100830T3 (da) * 1998-07-28 2004-01-19 Micromet Ag Heterominiantistoffer
DK1200479T3 (da) 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US20030232387A1 (en) * 2002-06-14 2003-12-18 Millennium Pharmaceuticals, Inc. Antibodies that bind alphaE integrin
AU2006250068A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
EA200802289A1 (ru) * 2006-05-08 2009-04-28 Филоджен Спа Направляемые к мишени антителами цитокины для терапии
BRPI0811857A2 (pt) * 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
CN108129573B (zh) * 2007-09-21 2021-10-08 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RU2014109038A (ru) * 2011-08-23 2015-09-27 Рош Гликарт Аг Антитела к хондроитинсульфат протеогликану меланомы
WO2013070076A1 (en) * 2011-11-08 2013-05-16 Umc Utrecht Holding B.V. Fusion protein comprising an interleukin 4 and interleukin
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CA2874864C (en) * 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL2970512T3 (pl) 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물

Also Published As

Publication number Publication date
US20170340708A1 (en) 2017-11-30
US11357826B2 (en) 2022-06-14
WO2016082677A1 (en) 2016-06-02
ES2752248T5 (es) 2023-11-10
EP3227342B2 (en) 2023-06-14
FI3227342T4 (fi) 2023-08-31
EP3227342B1 (en) 2019-09-18
DK3227342T3 (da) 2019-10-14
DK3227342T4 (da) 2023-07-10
ES2752248T3 (es) 2020-04-03
EP3227342A4 (en) 2018-04-11
JP6851314B2 (ja) 2021-03-31
US20200069773A1 (en) 2020-03-05
CN104403004B (zh) 2017-10-13
CN107001485A (zh) 2017-08-01
HRP20191807T1 (hr) 2019-12-27
JP6851314B6 (ja) 2021-04-21
EP3227342A1 (en) 2017-10-11
CN104403004A (zh) 2015-03-11
US10471124B2 (en) 2019-11-12
JP2018502147A (ja) 2018-01-25
CN107001485B (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
HRP20191807T4 (hr) Bjelančevinasti heterodimer i njegova uporaba
HRP20191470T1 (hr) Heterodimerni proteini
HRP20191865T1 (hr) Novi heterodimerni proteini
PH12019500782A1 (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
IL275743A (en) B-specific template suitable for use in High-Through-Put filtering
BR112015000798A2 (pt) heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
IL275270A (en) Recombinant scavenger cell surface proteins
HRP20191409T1 (hr) Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
HRP20191872T1 (hr) Sirp-alfa imunoglobulin fuzijski proteini
PE20210844A1 (es) Contorsbodies 2 + biespecificos
HRP20200464T1 (hr) Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera
PE20190514A1 (es) Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123
FI3390442T3 (fi) Anti-C5-vasta-aineita ja käyttömenetelmiä
EA201791366A1 (ru) Антитела к c5 и способы их применения
NZ710598A (en) Antibodies comprising chimeric constant domains
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
AR092050A1 (es) Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
MX2015012540A (es) Ratón de cadena ligera común.
NZ720765A (en) Antibodies and methods of use
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
PE20190415A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos